[HTML][HTML] Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
HA Hou, HF Tien - Journal of biomedical science, 2020 - Springer
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
[HTML][HTML] Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
HA Hou, HF Tien - Journal of Biomedical Science, 2020 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
[引用][C] Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
HA Hou, HF Tien - Journal of Biomedical Science (Web), 2020 - jglobal.jst.go.jp
Genomic landscape in acute myeloid leukemia and its implications in risk classification and
targeted therapies | Article Information | J-GLOBAL Art J-GLOBAL ID:202102226136463360 …
targeted therapies | Article Information | J-GLOBAL Art J-GLOBAL ID:202102226136463360 …
[PDF][PDF] Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
HA Hou, HF Tien - 2020 - scholar.archive.org
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
HA Hou, HF Tien - Journal of Biomedical Science, 2020 - search.proquest.com
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
HA Hou, HF Tien - Journal of biomedical science, 2020 - pubmed.ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
[HTML][HTML] Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
HA Hou, HF Tien - Journal of Biomedical Science, 2020 - jbiomedsci.biomedcentral.com
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
HA Hou, HF Tien - Journal of Biomedical Science, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Acute myeloid leukemia (AML) is a
heterogeneous hematologic malignancy in terms of clinical features, underlying …
heterogeneous hematologic malignancy in terms of clinical features, underlying …
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies.
HA Hou, HF Tien - Journal of Biomedical Science, 2020 - go.gale.com
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies.
HA Hou, HF Tien - Journal of Biomedical Science, 2020 - search.ebscohost.com
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …